Search 

SPAGO Imaging conducts research and development in the nanomedicine field with focus on diagnosis and treatment of cancer. The development is based on SPAGO's two proprietary platform technologies, IonXgel and 3PEG.

IonXgel is a unique nanomaterial and the basis for SPAGO’s novel cancer selective MRI contrast agent, SPAGO Pix. The SPAGO Pix portfolio also includes opportunities within cancer selective drug delivery for improved cancer treatment, as well as additional MR imaging indications. 

3PEG is a proprietary pegylation platform that can improve critical drug properties of small molecules, peptides and proteins, and provide e.g. increased efficacy and reduced side effects, and has therefore a broad clinical application.

SPAGO Imaging encompasses many years of experience from contrast- and pharma industry, including discovery research, early clinical- and business development.

The company was established in 2007 and is located in Lund, Sweden and employs a team of eight. SPAGO Imaging is publicly traded on the “Aktietorget” exchange in Stockholm.